Back to top

Image: Bigstock

Cardinal Health Inc.

Read MoreHide Full Article

Cardinal Health registered strong performance in the Medical segment. The Pharmaceutical segment also witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers. Further, the company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. A strong fiscal 2018 outlook buoys optimism. On the flip side, despite growth in business, profits at the Pharmaceutical segment were hurt by generic pharmaceutical pricing. Huge investments in Pharmaceutical IT platform and lackluster generics performance are likely to mar Cardinal Health’s operational efficiencies in the upcoming quarter. Intense competition and customer concentration are other bottlenecks. Recently, the company closed the divestiture of its Cardinal Health China distribution.Cardinal Health underperformed its industry in a year's time. 


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Cardinal Health, Inc. (CAH) - free report >>

Published in